Isabel Jones, APRN
Psychiatric/Mental Health · Lexington, KYNPI 1447877071
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.4% of the total across 347 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 15 manufacturers, the largest accounting for just 16.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $3,039, 4.3 times the $714 reported in 2022. Among psychiatric/mental health clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 347 payments — averaging $25.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Otsuka America Pharmaceutical, Inc.$1K
- Alkermes, Inc.$983
- Teva Pharmaceuticals USA, Inc.$887
- Johnson & Johnson$741
- AbbVie$728
- plus $3K from 9 others
What the payments were for
- Food & beverage$8,60297%
- Education$2263%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 59 | $1,465 |
| Otsuka America Pharmaceutical, Inc. | 49 | $1,156 |
| Alkermes, Inc. | 40 | $983 |
| Teva Pharmaceuticals USA, Inc. | 31 | $887 |
| Johnson & Johnson | 31 | $741 |
| AbbVie | 35 | $728 |
| Vanda Pharmaceuticals Inc. | 16 | $558 |
| Neurocrine Biosciences, Inc. | 26 | $548 |
| E.r. Squibb & Sons, L.L.C. | 19 | $456 |
| Axsome Therapeutics, Inc. | 8 | $443 |
| Lundbeck LLC | 18 | $316 |
| Indivior Inc. | 12 | $185 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $154 |
| Mylan Specialty L.p. | 1 | $121 |
| Sumitomo Pharma America, Inc. | 1 | $89 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$960
- CAPLYTA$795
- VRAYLAR$345
- INGREZZA$339
- Auvelity$331
- INVEGA SUSTENNA$147
- Austedo XR$138
- UZEDY$126
- Yupelri$121
- ABILIFY MAINTENA$121
- Fanapt$119
- REXULTI$111
How this compares
$8,828 in reported general payments places this provider in the 95th percentile of 946 psychiatric/mental health providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 115 | $369,275 |
| AristadaAripiprazole Lauroxil | 56 | $184,671 |
| IngrezzaValbenazine Tosylate | 22 | $174,622 |
| Invega TrinzaPaliperidone Palmitate | 14 | $153,237 |
| Abilify MaintenaAripiprazole | 44 | $128,500 |
| VraylarCariprazine Hcl | 84 | $121,181 |
| PerserisRisperidone | 29 | $87,171 |
| RexultiBrexpiprazole | 46 | $64,256 |
| UzedyRisperidone | 16 | $63,974 |
| NuplazidPimavanserin Tartrate | 13 | $62,573 |
| CaplytaLumateperone Tosylate | 17 | $28,639 |
| LybalviOlanzapine/Samidorphan Malate | 16 | $23,726 |
| Fluphenazine Decanoate | 67 | $7,462 |
| Divalproex Sodium | 130 | $3,935 |
| Aripiprazole | 64 | $3,265 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Invega Trinza | $741 | $522,513129 claims |
| Alkermes, Inc.Aristada, Lybalvi | $983 | $208,39772 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $1,156 | $192,75690 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $548 | $174,62222 claims |
| AbbVieVraylar | $728 | $121,18184 claims |
| Indivior Inc.Perseris | $185 | $87,17129 claims |
| Teva Pharmaceuticals USA, Inc.Uzedy | $887 | $63,97416 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,465 | $28,63917 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 946 psychiatric/mental health providers in Kentucky.
Other psychiatric/mental health in Lexington
- Adam LooseLexington$44K
- Lauren WilliamsLexington$40K
- Laura ThomsonLexington$25K
- Laura WeddleLexington$15K
- Latoya LeeLexington$12K
- Theresa WattsAshland$645K
- Rachel ColeHopkinsville$503K
- Denise de AngelisLouisville$384K
- Jennifer SampangCrestview Hills$322K
- Jeremy FisherSouth Shore$197K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.